공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

코로나바이러스 감염증 : 파이프라인 리뷰

Coronaviridae Infections - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 08월 상품 코드 371013
페이지 정보 영문 101 Pages
가격
US $ 2,000 ₩ 2,307,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,614,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,921,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


코로나바이러스 감염증 : 파이프라인 리뷰 Coronaviridae Infections - Pipeline Review, H2 2016
발행일 : 2016년 08월 페이지 정보 : 영문 101 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

코로나바이러스는 대부분의 사람이 일생동안 몇 번 감염되는 바이러스입니다. 인간 코로나바이러스는 보통 경도에서부터 중도의 상부 기도 질환을 일으킵니다. 이 바이러스는 기침이나 재채기 등의 공기 감염, 접촉, 악수 등 밀접한 접촉에 의해서 감염자로부터 다른 사람에게 옮겨집니다. 증후는 비루, 재채기, 기침, 비폐색, 기관지염 등입니다. 치료에는 항바이러스제나 진통제를 이용합니다.

코로나바이러스 감염증(Coronaviridae Infections) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

코로나바이러스 감염증 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품 상황 개요

  • 임상시험 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • AstraZeneca Plc
  • CEL-SCI Corporation
  • GeneCure LLC
  • Gilead Sciences, Inc.
  • Hemispherx Biopharma, Inc.
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Nanotherapeutics, Inc.
  • NanoViricides, Inc.
  • Novavax, Inc.
  • Organic Vaccines
  • Phelix Therapeutics, LLC
  • Planet Biotechnology Inc.
  • Protein Sciences Corporation
  • Regeneron Pharmaceuticals Inc

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용요법 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 16.10.07

Summary:

Global Markets Direct's, 'Coronaviridae Infections - Pipeline Review, H2 2016', provides an overview of the Coronaviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Coronaviridae Infections
  • The report reviews pipeline therapeutics for Coronaviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Coronaviridae Infections therapeutics and enlists all their major and minor projects
  • The report assesses Coronaviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Coronaviridae Infections

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Coronaviridae Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coronaviridae Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronaviridae Infections Overview
  • Therapeutics Development
    • Pipeline Products for Coronaviridae Infections - Overview
    • Pipeline Products for Coronaviridae Infections - Comparative Analysis
  • Coronaviridae Infections - Therapeutics under Development by Companies
  • Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes
  • Coronaviridae Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Coronaviridae Infections - Products under Development by Companies
  • Coronaviridae Infections - Products under Investigation by Universities/Institutes
  • Coronaviridae Infections - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • CEL-SCI Corporation
    • GeneCure LLC
    • Gilead Sciences, Inc.
    • Hemispherx Biopharma, Inc.
    • Humabs BioMed SA
    • Inovio Pharmaceuticals, Inc.
    • Kineta, Inc.
    • Nanotherapeutics, Inc.
    • NanoViricides, Inc.
    • Novavax, Inc.
    • Organic Vaccines
    • Phelix Therapeutics, LLC
    • Planet Biotechnology Inc.
    • Protein Sciences Corporation
    • Regeneron Pharmaceuticals Inc
  • Coronaviridae Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-3252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBR-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-n3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCA-60 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Coronavirus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for SARS Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBD-219N1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3048 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAB-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SARS (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 3CLpro for Coronavirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Coronaviridae Infections - Dormant Projects
  • Coronaviridae Infections - Discontinued Products
  • Coronaviridae Infections - Product Development Milestones
    • Featured News & Press Releases
      • Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
      • Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine
      • Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome
      • Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals' MERS Vaccine Approved for First-in-Human Study
      • Oct 19, 2015: Inovio and Partner Advance MERS Vaccine
      • Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome
      • Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS
      • Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome
      • Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials
      • Jun 04, 2015: Kineta's Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
      • Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
      • Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus
      • Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Coronaviridae Infections, H2 2016
  • Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Coronaviridae Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Coronaviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016
  • Coronaviridae Infections - Pipeline by GeneCure LLC, H2 2016
  • Coronaviridae Infections - Pipeline by Gilead Sciences, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Humabs BioMed SA, H2 2016
  • Coronaviridae Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Kineta, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by NanoViricides, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Novavax, Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Organic Vaccines, H2 2016
  • Coronaviridae Infections - Pipeline by Phelix Therapeutics, LLC, H2 2016
  • Coronaviridae Infections - Pipeline by Planet Biotechnology Inc., H2 2016
  • Coronaviridae Infections - Pipeline by Protein Sciences Corporation, H2 2016
  • Coronaviridae Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Coronaviridae Infections - Dormant Projects, H2 2016
  • Coronaviridae Infections - Dormant Projects (Contd..1), H2 2016
  • Coronaviridae Infections - Dormant Projects (Contd..2), H2 2016
  • Coronaviridae Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Coronaviridae Infections, H2 2016
  • Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top
전화 문의
F A Q